The company, which is also backed by Health Innovation Manchester, aims to expedite the commercialization of biomarkers into new diagnostic tests.
The company's new KidneyCare test will include AlloSure for rejection, AlloMap for quiescence, and Cibiltech's AI algorithm for graft health information.
The microfluidic immunoassay uses spectrometry and a lateral flow method to diagnose the "very large global health problem" in about 20 minutes.
The company and Women & Infants Hospital of Rhode Island are currently evaluating the technology to determine the performance of the test.
Dian selected the MassArray system as its platform of choice for molecular genetic testing and will commercialize it and Agena's DNA applications and products.
The collaboration will give the company access to UCI research in diagnostic platforms, life science applications, devices, and data analytics.
With European Union funds, the firm is accelerating its go-to-market strategy for the PrePsia four-metabolite, mass spec-based blood test for preterm preeclampsia.
The company plans to launch the system this summer in Europe, aiming to broaden cell-free DNA screening for trisomy 21, 18, and 13.
The company said that the funds will allow it to take its ReadyPlex rapid blood group genotyping assays into clinical trials and commercialization.
The firm said that the push toward outcomes-based medicine will drive innovation in diagnostic wearables and smart textiles over the next few years.